$12.850
-0.407 (-3.17%)At close
KLRA Comparative Benchmarking
In the context of the broader market, KLRA competes directly with industry leaders such as ANIP and URGN. With a market capitalization of $1.67B, it holds a leading position in the sector. When comparing efficiency, KLRA's gross margin of N/A stands against ANIP's 54.97% and URGN's 90.93%. Such benchmarking helps identify whether Kailera Therapeutics Inc is trading at a premium or discount relative to its financial performance.
Kailera Therapeutics Inc Financial Performance
Kailera has shown a significant increase in current assets, rising from 530,315,000 USD in Q1 2026 to 929,167,000 USD in Q2 2026, indicating improved liquidity. However, the company is still facing large net losses, with EPS reported at -1.09 for Q2 2026.
Financials
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.